{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:22:19Z","timestamp":1783786939111,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.ygyno.2011.08.033","type":"journal-article","created":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T15:07:26Z","timestamp":1317222446000},"page":"499-504","source":"Crossref","is-referenced-by-count":47,"title":["Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I\/II study of the Hoosier Oncology Group"],"prefix":"10.1016","volume":"123","clinical-trial-number":[{"clinical-trial-number":"nct00526799","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"R.","family":"Ramasubbaiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.S.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Matei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ygyno.2011.08.033_bb0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.ygyno.2011.08.033_bb0010","series-title":"SEER Cancer Statistics Review, 1975\u20132006","author":"Horner","year":"2009"},{"issue":"14","key":"10.1016\/j.ygyno.2011.08.033_bb0015","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2011.08.033_bb0020","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1006\/gyno.2001.6435","article-title":"A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients","volume":"83","author":"Homesley","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2011.08.033_bb0025","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ygyno.2008.02.028","article-title":"Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers","volume":"109","author":"Morris","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2011.08.033_bb0030","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ygyno.2004.09.005","article-title":"Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer","volume":"95","author":"Levy","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2011.08.033_bb0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2006.11.017","article-title":"Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer","volume":"105","author":"Safra","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"5443","key":"10.1016\/j.ygyno.2011.08.033_bb0040","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1126\/science.286.5443.1358","article-title":"Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms","volume":"286","author":"Bonni","year":"1999","journal-title":"Science"},{"issue":"5979","key":"10.1016\/j.ygyno.2011.08.033_bb0045","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/310628a0","article-title":"Cancer: mutant ras proteins and cell transformation","volume":"310","author":"Newbold","year":"1984","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ygyno.2011.08.033_bb0050","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1073\/pnas.91.16.7558","article-title":"A human oncogene of the RAS superfamily unmasked by expression cDNA cloning","volume":"91","author":"Chan","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.ygyno.2011.08.033_bb0055","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/dna.1993.12.623","article-title":"Point mutation of the ras oncogene in human ovarian cancer","volume":"12","author":"Chien","year":"1993","journal-title":"DNA Cell Biol"},{"issue":"2","key":"10.1016\/j.ygyno.2011.08.033_bb0060","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1158\/1078-0432.CCR-0754-03","article-title":"Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation","volume":"10","author":"Matei","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.ygyno.2011.08.033_bb0065","first-page":"4550","article-title":"Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms","volume":"53","author":"Henriksen","year":"1993","journal-title":"Cancer Res"},{"issue":"25","key":"10.1016\/j.ygyno.2011.08.033_bb0070","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2174\/1381612023393026","article-title":"BAY 43\u20139006: preclinical data","volume":"8","author":"Wilhelm","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ygyno.2011.08.033_bb0075","doi-asserted-by":"crossref","unstructured":"Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011 Jan 1;29(1):69\u201375.","DOI":"10.1200\/JCO.2009.26.7856"},{"issue":"3","key":"10.1016\/j.ygyno.2011.08.033_bb0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ygyno.2011.08.033_bb0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10543400902802466","article-title":"Some notable properties of the standard oncology Phase I design","volume":"19","author":"Hather","year":"2009","journal-title":"J Biopharm Stat"},{"issue":"5","key":"10.1016\/j.ygyno.2011.08.033_bb0090","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1525-1438.2005.00130.x","article-title":"CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use","volume":"15","author":"Duffy","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.08.033_bb0095","doi-asserted-by":"crossref","unstructured":"Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2011 Jan 10;29(2):242\u20138.","DOI":"10.1200\/JCO.2009.27.8911"},{"issue":"19","key":"10.1016\/j.ygyno.2011.08.033_bb0100","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","article-title":"Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"26","author":"Sehouli","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2011.08.033_bb0105","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ygyno.2009.08.024","article-title":"Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study","volume":"115","author":"Joly","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.033_bb0110","doi-asserted-by":"crossref","unstructured":"Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and\/or recurrent gynecologic malignancies. Gynecol Oncol 2010 Jun;117(3):473\u20136.","DOI":"10.1016\/j.ygyno.2010.02.022"},{"issue":"3","key":"10.1016\/j.ygyno.2011.08.033_bb0115","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1525-1438.2007.01041.x","article-title":"Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer","volume":"18","author":"Le","year":"2008","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2011.08.033_bb0120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2007.08.062","article-title":"Weekly topotecan for recurrent platinum resistant ovarian cancer","volume":"108","author":"Abushahin","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2011.08.033_bb0125","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ygyno.2010.01.040","article-title":"Assessment of tumor response as a surrogate endpoint of survival in recurrent\/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study","volume":"117","author":"Rose","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.033_bb0130","doi-asserted-by":"crossref","unstructured":"Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010 Apr 10;28(11):1835\u201342.","DOI":"10.1200\/JCO.2009.26.1321"},{"issue":"15s","key":"10.1016\/j.ygyno.2011.08.033_bb0135","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/jco.2010.28.15_suppl.4066","article-title":"Sorafenib plus chemotherapy versus chemotherapy alone in advanced pancreatic cancer: a randomized phase II trial","volume":"28","author":"Cascinu RB","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.033_bb0140","doi-asserted-by":"crossref","unstructured":"Kessler T, Bayer M, Schwoppe C, Liersch R, Mesters RM, Berdel WE. Compounds in clinical Phase III and beyond. Recent Results Cancer Res.180:137\u201363.","DOI":"10.1007\/978-3-540-78281-0_9"},{"issue":"15s","key":"10.1016\/j.ygyno.2011.08.033_bb0145","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1200\/jco.2010.28.15_suppl.1093","article-title":"Phase Ib study of sorafenib and vinorelbine as first-line treatment in patients with metastatic breast cancer","volume":"28","author":"Ferrario HC","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18s","key":"10.1016\/j.ygyno.2011.08.033_bb0150","article-title":"Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC)","volume":"28","author":"Crown VD","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811007189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811007189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,16]],"date-time":"2019-06-16T13:40:07Z","timestamp":1560692407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811007189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0090825811007189"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.08.033","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}